Curaleaf (CURA) AGM 2024 summary
Event summary combining transcript, slides, and related documents.
AGM 2024 summary
3 Feb, 2026Opening remarks and agenda
Meeting held virtually to enhance accessibility and shareholder engagement, with clear rules for participation and voting established at the outset.
Attendees were thanked for proxy submissions and informed about the use of technology for broader participation.
The agenda included presentation of financial statements, board elections, auditor appointment, and a Q&A session.
Corporate governance
Quorum was confirmed with at least two shareholders present by proxy, meeting requirements to proceed.
Proper notice of the meeting was confirmed, and official records were maintained as per legal requirements.
The number of directors was set at 10, with the board empowered to fill two vacancies until the next AGM.
Board and executive committee updates
Eight individuals were nominated and elected to the board, each qualifying under relevant corporate law.
No additional nominations were received, and all nominees confirmed willingness to serve.
Latest events from Curaleaf
- Q2 2026 revenue rose 10% to $340M, with $12.5M net income and strong international growth.CURA
Q2 2026 - All resolutions, including U.S. continuation and board elections, were approved without dissent.CURA
AGM 2026 - Q1 2026 revenue rose 6% to $324M, with $70M net income and strong global expansion.CURA
Q1 2026 - Q4 2025 revenue hit $333M, margins improved, and international revenue grew 65% year-over-year.CURA
Q4 2025 - Six directors elected, board set at 10, and auditor appointed with no shareholder questions.CURA
AGM 2025 - Q3 revenue hit $320M, with 56% international growth and improved margins despite price pressure.CURA
Q3 2025 - Q3 saw $331M revenue, 49% gross margin, and 82% international growth amid U.S. headwinds.CURA
Q3 2024 - Q2 revenue up 2% to $342M, with 78% international growth and 48% adjusted gross margin.CURA
Q2 2024 - 2024 revenue flat at $1.34B; international sales up 73% and margins improved.CURA
Q4 2024